Trends and Predictors of Smoking Cessation After Percutaneous Coronary Intervention (from Olmsted County, Minnesota, 1999 to 2010)

Sochor, Ondřej; Lennon, Ryan J.; Rodriguez-Escudero, Juan P.; Bresnahan, John F.; Croghan, Ivana T.; Somers, Virend K.; López-Jiménez, Francisco; Pack, Quinn R.; Thomas, Randal J.

doi:10.1016/j.amjcard.2014.11.020

Cited by 29 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study is a contemporary one where the majority of STEMI patients undergo primary PCI with an almost non-existing role for thrombolysis in the participating hospitals, and 60-70% of NSTEACS patients undergo coronary angiography and coronary revascularization. Absence of smoker's paradox; despite younger age and better clinical profile of smokers; strengthens the notion that smoking per se adversely affects the atherosclerotic disease severity, despite the fact that a minority of smokers in quit smoking after sustaining ACS [34]. The increasing frequency of studies refuting "smoker's paradox" during the last decade supports the argument that the paradox was due to confounding factors that were not adjusted for.…”

Section: Discussionsupporting

confidence: 48%

Absence of Smoker’s Paradox in Middle Eastern Patients with Acute Coronary Syndrome

Saleh¹

2016

Vasc Med Surg

View full text Add to dashboard Cite

Studies have shown that smokers admitted with acute coronary syndrome (ACS) have an apparent lower inhospital and long term mortality rates compared with nonsmokers ("smoker's paradox"). This study was done to test if the "smoker's paradox" exists in Middle Eastern ACS patients. A 1618 consecutive patients admitted with acute coronary syndrome in 4 tertiary hospitals were enrolled. We compared clinical and coronary angiographic features and mortality during admission and after one year among smokers vs. non-smokers. Of the whole group (N=1618); smokers (N=859; 53%) were younger than non-smokers (Mean age 50+7 vs. 63+9 year; P=0.005), more likely to be male (96% vs. 69%; P<0.001), and less likely to have hypertension (33% vs. 67%; P<0.001) and diabetes mellitus (29% vs. 50%; P<0.001). Smokers were more likely to have ST-segment elevation myocardial infarction (STEMI) than non-smokers (35% vs. 24%; P<0.001) and less likely to have non ST-segment elevation ACS (65% vs. 76%; P=0.005). Compared with non-smokers; smokers had similar incidence of anterior wall MI (51.7% vs. 53.9%; P=NS), higher incidence of single vessel disease (54% vs. 47%; P=0.002) and lower incidence of multi vessel disease (44% vs. 51%; P=0.005). There were no statistically significant differences between the in-hospital (3.2% vs. 2.2%; =0.29) and 1-year (6.5% vs. 7.0%; P=0.92) mortality rates in smoker sand non-smokers; respectively. Despite being younger with less prevalence of comorbid diseases, multivessel coronary artery disease, and low TIMI risk scores; smokers in the Middle East with ACS did not have a better in-hospital or 1 year out come compared with nonsmokers.

show abstract

Section: Discussionsupporting

confidence: 48%

Absence of Smoker’s Paradox in Middle Eastern Patients with Acute Coronary Syndrome

Saleh¹

2016

Vasc Med Surg

View full text Add to dashboard Cite

show abstract

“…While cardiac patients who use tobacco would benefit from quitting smoking, most cardiac patients who smoke resume smoking within 6 months of diagnosis (Barth et al, 2015). Additionally, smoking cessation rates following a cardiac event have not increased over time as they have in the general population (Sochor et al, 2015). Despite the importance of being tobacco-free among patients with medical conditions, coping with withdrawal symptoms while managing the stress associated with having chronic health problems may create additional barriers to cessation.…”

Section: Introductionmentioning

confidence: 99%

Trends in tobacco use among US adults with chronic health conditions: National Survey on Drug Use and Health 2005–2013

Stanton

Keith

Gaalema

et al. 2016

Preventive Medicine

View full text Add to dashboard Cite

Introduction Chronic conditions are among the most common and costly of all health problems. Addressing tobacco use among adults with chronic conditions is a public health priority due to high prevalence as well as greater potential harm from continued use. Methods Data were drawn from 9 years (2005–2013) of the U.S. National Survey on Drug Use and Health. Adult (≥18 years) tobacco use included any past 30-day use of cigarettes, cigars, pipes, or smokeless tobacco. Chronic conditions examined included anxiety, asthma, coronary heart disease, depression, diabetes, hepatitis, HIV, hypertension, lung cancer, stroke, and substance abuse. Controlling for sociodemographics, trends in product use for most conditions and a composite of any condition among those with chronic conditions were compared to respondents with no condition in weighted logistic regression analyses. Results Cigarette smoking declined significantly over time among adults with no chronic condition. Adults with one or more chronic condition showed no comparable decrease, with cigarette smoking remaining especially high among those reporting anxiety, depression, and substance abuse. Cigar and pipe use remained stable and more prevalent among those with any chronic condition, with the exception of pipe use declining among those with heart disease. Smokeless tobacco use increased over time, with higher prevalence among those with asthma, mental health, and substance abuse conditions. Conclusions These findings have tobacco control and regulatory implications for addressing higher tobacco use among adults with chronic conditions. Provider advice and cessation resources targeting tobacco use among those with chronic conditions are recommended.

show abstract

“…Nearly 20% of US adults continue to smoke, 14 and multiple contemporary studies demonstrate that quit rates after MI remain <50%. 10,[15][16][17] Although as a nation we have done a much better job at implementing other secondary prevention medications, improvements in the rate of smoking cessation has been a disappointing outlier. 18 Why the lack of progress?…”

Section: See Article By Jang Et Almentioning

confidence: 99%

“…Participation in cardiac rehabilitation has been associated with higher rates of smoking cessation, with up to a 3-fold increase seen in the odds of tobacco cessation among adults who participated in cardiac rehabilitation. 10,22 Pharmacological interventions for smoking cessation have shown some success but seem to be underused. 23 For example, a large post-MI registry found that only 14% of smokers were prescribed smoking cessation medications at discharge.…”

Section: See Article By Jang Et Almentioning

confidence: 99%

“…Even in contemporary practice, those who quit smoking after an MI have significantly lower risks of future mortality and recurrent events relative to those who continue to smoke. [8][9][10] Although these effects on hard cardiovascular end points are impressive, smoking cessation has also been linked to improvements in patient quality of life, functional status, and angina control.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Smoke Signals

Návar

Peterson

2015

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Trends and Predictors of Smoking Cessation After Percutaneous Coronary Intervention (from Olmsted County, Minnesota, 1999 to 2010)

Cited by 29 publications

References 17 publications

Absence of Smoker’s Paradox in Middle Eastern Patients with Acute Coronary Syndrome

Absence of Smoker’s Paradox in Middle Eastern Patients with Acute Coronary Syndrome

Trends in tobacco use among US adults with chronic health conditions: National Survey on Drug Use and Health 2005–2013

Smoke Signals

Contact Info

Product

Resources

About